Would you recommend PARP inhibitor maintenance for a BRCA wild-type, HRD+ advanced ovarian cancer?

We have a better understanding of ovarian cancer biology now, including the importance of germline and somatic BRCA mutations, as well as the role of homologous recombination deficiency (HRD) in tumors and the potential benefit of new therapies in the maintenance.

Considerations for maintenance thera...

Yes. In clinical practice, I discuss and recommend PARP inhibitor maintenance therapy for patients who are HRD+. This recommendation is informed by data from both PAOLA-1 as well as PRIMA clinical trials. In both of these studies, the magnitude of benefit with PARP inhibitor maintenance strategies w...